Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Univ. of South China VEGFR2 compound 6r
- Development stage
- Unknown
- Lead developer
- University of South China
01
Overview
Univ. of South China VEGFR2 compound 6r: sourced facts only. name: "Mechanistic studies revealed that 6r exerted antitumor activity by inhibiting VEGFR2 and tubulin in the micromolar range." [PMID:40609278]; target: "Mechanistic studies revealed that 6r exerted antitumor activity by inhibiting VEGFR2 and tubulin in the micromolar range." [PMID:40609278]; developer: "The First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang 421001, Hunan, China." [PMID:40609278]; stage: "Notably, 6r inhibited tumor growth in the HGC-27 xenograft model." [PMID:40609278]
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on Univ. of South China VEGFR2 compound 6r.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Univ. of South China VEGFR2 compound 6r.